These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21140557)

  • 1. [Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)].
    Loginova SIa; Borisevich SV; Shkliaeva OM; Maksimov VA; Bondarev VP; Nebol'sin VE
    Antibiot Khimioter; 2010; 55(7-8):10-2. PubMed ID: 21140557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)].
    Loginova SIa; Borisevich SV; Maksimov VA; Bondarev VP; Nebol'sin VE
    Antibiot Khimioter; 2008; 53(7-8):27-30. PubMed ID: 19227120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiviral activity of Ingavirin in experimental lethal influenza due to influenza virus B in albino mice].
    Zarubaev VV; Garshinina AV; Kalinina NA; Shtro AA; Nebol'sin VE; Kiselev OI
    Antibiot Khimioter; 2010; 55(3-4):8-11. PubMed ID: 20695201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of Ingavirin antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro and in vivo].
    Loginova SY; Borisevich SV; Shchukina VN; Lykov MV; Borisevich GV; Bondarev VP; Nebolsin VE; Sutochnikova OA; Chychalin AG
    Antibiot Khimioter; 2010; 55(11-12):17-21. PubMed ID: 21574420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models].
    Leneva IA; Fediakina IT; Eropkin MIu; Gudova NV; Romanovskaia AA; Danilenko DM; Vinogradova SM; Lepeshkin AIu; Shestopalov AM
    Vopr Virusol; 2010; 55(3):19-27. PubMed ID: 20608077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].
    Shishkina LN; Nebol'sin VE; Skarnovich MO; Kabanov AS; Sergeev AA; Erdyneeva UB; Serova OA; Demina OK; Agafonov AP; Stavskiĭ EA; Drozdov IG
    Antibiot Khimioter; 2010; 55(5-6):32-5. PubMed ID: 21033472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective activity of Ingavirin in experimental lethal influenza due to pandemic influenza virus A (H1N1)v in albino mice].
    Zarubaev VV; Garshinina AV; Kalinina NA; Shtro AA; Beliaevskaia SV; Nebol'sin VE; Kiselev OI
    Antibiot Khimioter; 2010; 55(5-6):24-31. PubMed ID: 21033471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of prophylactic activity of Ingavirin, a new Russian drug, against grippe A virus (H3N2)].
    Loginova SIa; Borisevich SV; Maksimov VA; Bondarev VP; Nebol'sin VE
    Antibiot Khimioter; 2008; 53(11-12):19-21. PubMed ID: 19441652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v].
    Shishkina LN; Nebol'sin VE; Kabanov AS; Skarnovich MO; Mazurkova NA; Sergeev AA; Serova OA; Stavskiĭ EA; Drozdov IG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):93-6. PubMed ID: 21598625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pandemic influenza in Russia: specific features of clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease].
    Kolobukhina LV; Merkulova LN; Shchelkanov MIu; Burtseva EI; Lavrishcheva VV; Samokhvalov EI; Al'khovskiĭ SV; Prilipov AG; Proshina ES; Avdeev SN; Sutochnikova OA; Bazarova MV; Kelli EI; Tserukalova ND; Blank IA; Shestakova OM; Kolivashko ON; Arseneva TV; Ambrosi OE; Shul'diakov AA; Popov AF; Simakova AI; Malyshev NA; Chuchalin AG; L'vov DK
    Ter Arkh; 2011; 83(9):48-53. PubMed ID: 22145388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)].
    Loginova SIa; Borisevich SV; Maksimov VA; Bondarev VP; Kotovskaia SK; Rusinov VL; Charushin VN; Chupakhin ON
    Antibiot Khimioter; 2010; 55(9-10):25-8. PubMed ID: 21400750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of ingavirin in adults with influenza].
    Kolobukhina LV; Merkulova LN; Shchelkanov MIu; Burtseva EI; Isaeva EI; Malyshev NA; L'vov DK
    Ter Arkh; 2009; 81(3):51-4. PubMed ID: 19459424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro efficacy of Ingavirin against the pandemic influenza virus A(H1N1/09)v].
    Shishkina LN; Nebol'sin VE; Kabanov AS; Skarnovich MO; Erdyneeva UB; Mazurkova NA; Serova OA; Stavskiĭ EA; Drozdov IG
    Antibiot Khimioter; 2010; 55(3-4):12-6. PubMed ID: 20695202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro and in vivo effects of ingavirin on the ultrastructure and infectivity of influenza virus].
    Zarubaev VV; Beliaevskaia SV; Sirotkin AK; Anfimov PM; Nebol'sin VE; Kiselev OI; Reĭkhart DV
    Vopr Virusol; 2011; 56(5):21-5. PubMed ID: 22171473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro efficacy of ingavirin against the Mexican pandemic subtype H1N1 of influenza A virus, strains A/California/04/2009 and A/California/07/2009].
    Loginova SIa; Borisevich SV; Lykov MV; Vedenina EV; Borisevich GV; Bondarev VP; Nebol'sin VE; Chuchalin AG
    Antibiot Khimioter; 2009; 54(3-4):15-7. PubMed ID: 19711843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiviral etiotropic chemicals: efficacy against influenza A viruses A subtype H5N1].
    Leneva IA; Shuster AM
    Vopr Virusol; 2006; 51(5):4-7. PubMed ID: 17087058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of therapeutic and protective effect of Reaferon-ES Lipint on mice infected with avian influenza virus (subtype H5N1)].
    Demina OK; Sergeev AA; Agafonov AP; Shikov AN; Sementsova AO; Sergeev AA; Sergeev AN; Drozdov IG
    Antibiot Khimioter; 2009; 54(9-10):27-9. PubMed ID: 20415260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
    Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
    J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
    Koudstaal W; Koldijk MH; Brakenhoff JP; Cornelissen LA; Weverling GJ; Friesen RH; Goudsmit J
    J Infect Dis; 2009 Dec; 200(12):1870-3. PubMed ID: 19911992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro activity of Ingavirin against influenza virus A (H3N2)].
    Loginova SIa; Borisevich SV; Semenova IV; Maksimov VA; Bondarev VP; Nebol'sin VE
    Antibiot Khimioter; 2009; 54(9-10):23-6. PubMed ID: 20415259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.